WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H598124
CAS#: 137863-20-8
Description: Valsartan benzyl ester is a Valsartan intermediate.
Hodoodo Cat#: H598124
Name: Valsartan benzyl ester
CAS#: 137863-20-8
Chemical Formula: C31H35N5O3
Exact Mass: 525.27
Molecular Weight: 525.650
Elemental Analysis: C, 70.83; H, 6.71; N, 13.32; O, 9.13
Synonym: Valsartan benzyl ester; Valsartan impurity B; Valsartan related compound C;
IUPAC/Chemical Name: benzyl N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate
InChi Key: VXKKFWDUSKMRNO-LJAQVGFWSA-N
InChi Code: InChI=1S/C31H35N5O3/c1-4-5-15-28(37)36(29(22(2)3)31(38)39-21-24-11-7-6-8-12-24)20-23-16-18-25(19-17-23)26-13-9-10-14-27(26)30-32-34-35-33-30/h6-14,16-19,22,29H,4-5,15,20-21H2,1-3H3,(H,32,33,34,35)/t29-/m0/s1
SMILES Code: CC(C)[C@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(OCC4=CC=CC=C4)=O
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 525.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ardiana F, Suciati, Indrayanto G. Valsartan. Profiles Drug Subst Excip Relat Methodol. 2015;40:431-93. doi: 10.1016/bs.podrm.2015.01.004. Epub 2015 Mar 21. Review. PubMed PMID: 26051690.
2: Jung JA, Lee SY, Kim JR, Ko JW, Jang SB, Nam SY, Huh W. A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Drug Des Devel Ther. 2015 Mar 2;9:745-52. doi: 10.2147/DDDT.S76942. eCollection 2015. PubMed PMID: 25767372; PubMed Central PMCID: PMC4354399.
3: Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD; PARADIGM-HF Investigators. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. N Engl J Med. 2015 Dec 3;373(23):2289-90. doi: 10.1056/NEJMc1509753. PubMed PMID: 26630151.
4: Zhi-Bin H, Chang F, Mao-Huan L, Gui-Yi Y, Shu-Xian Z, Wei W. Valsartan improves the electrophysiological characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive rats. Hypertens Res. 2014 Sep;37(9):824-9. doi: 10.1038/hr.2014.85. Epub 2014 Apr 24. PubMed PMID: 24758867.
5: Sunkara G, Jiang X, Reynolds C, Serra D, Zhang Y, Ligueros-Saylan M, Ayalasomayajula S, Winter S, Jarugula V. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects. Clin Pharmacol Drug Dev. 2014 Nov;3(6):487-92. doi: 10.1002/cpdd.131. Epub 2014 Jun 2. PubMed PMID: 27129123.
6: Ushijima K, Nakashima H, Shiga T, Harada K, Ishikawa S, Ioka T, Ando H, Fujimura A. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning. J Pharmacol Sci. 2015 Jan;127(1):62-8. doi: 10.1016/j.jphs.2014.09.004. Epub 2014 Oct 2. PubMed PMID: 25704020.
7: Mancia G, Asmar R, Amodeo C, Mourad JJ, Taddei S, Gamba MA, Chazova IE, Puig JG. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens. 2015 Feb;33(2):401-11. doi: 10.1097/HJH.0000000000000409. PubMed PMID: 25380149.
8: Zappe DH, Crikelair N, Kandra A, Palatini P. Time of administration important? Morning versus evening dosing of valsartan. J Hypertens. 2015 Feb;33(2):385-92. doi: 10.1097/HJH.0000000000000397. PubMed PMID: 25259546; PubMed Central PMCID: PMC4284009.
9: Lee KR, Nguyen NT, Lee YJ, Choi S, Kang JS, Mar W, Kim KH. Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis. Arch Pharm Res. 2015;38(5):826-33. doi: 10.1007/s12272-014-0449-7. Epub 2014 Jul 23. PubMed PMID: 25052956.
10: Shao D, Zhang YF, Zhan Y, Chen XY, Zhong DF. [Troubleshooting of bioinequivalence of compound valsartan tablets]. Yao Xue Xue Bao. 2014 Apr;49(4):524-9. Chinese. PubMed PMID: 24974472.
11: Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P. A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. Am J Ther. 2015 Sep-Oct;22(5):e130-40. doi: 10.1097/MJT.0000000000000247. PubMed PMID: 25853236; PubMed Central PMCID: PMC4585485.
12: Ecder T. Renal and metabolic effects of valsartan. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S14-9. doi: 10.5152/akd.2014.00003. Review. PubMed PMID: 25604203.
13: Kusaka H, Sueta D, Koibuchi N, Hasegawa Y, Nakagawa T, Lin B, Ogawa H, Kim-Mitsuyama S. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. Am J Hypertens. 2015 Dec;28(12):1409-17. doi: 10.1093/ajh/hpv015. Epub 2015 Mar 10. PubMed PMID: 25762811.
14: Zhu D, Yang K, Sun N, Gao P, Wang R, Grosso A, Zhang Y; trial investigators. Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. Int J Cardiol. 2013 Sep 1;167(5):2024-30. doi: 10.1016/j.ijcard.2012.05.039. Epub 2012 May 28. PubMed PMID: 22647413.
15: Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Des Devel Ther. 2014 Oct 8;8:1781-8. doi: 10.2147/DDDT.S68574. eCollection 2014. PubMed PMID: 25336921; PubMed Central PMCID: PMC4199974.
16: Sui X, Wei H, Wang D. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med. 2015 Aug;19(8):1773-82. doi: 10.1111/jcmm.12551. Epub 2015 Mar 30. PubMed PMID: 25823960; PubMed Central PMCID: PMC4549028.
17: Liu L, Geng J, Zhao H, Yun F, Wang X, Yan S, Ding X, Li W, Wang D, Li J, Pan Z, Gong Y, Tan X, Li Y. Valsartan Reduced Atrial Fibrillation Susceptibility by Inhibiting Atrial Parasympathetic Remodeling through MAPKs/Neurturin Pathway. Cell Physiol Biochem. 2015;36(5):2039-50. doi: 10.1159/000430171. Epub 2015 Jul 17. PubMed PMID: 26202363.
18: Zaid AN, Assali M, Qaddomi A, Ghanem M, Zaaror YA. Preparation and stability evaluation of extemporaneous oral suspension of valsartan using commercially available tablets. Int J Pharm Compd. 2014 Mar-Apr;18(2):169-74. PubMed PMID: 24881122.
19: Can B, Sali M, Batman A, Yilmaz H, Korkmaz U, Celebi A, Senturk O, Hulagu S. Valsartan-induced acute pancreatitis. Intern Med. 2014;53(7):703-5. Epub 2012 Mar 1. PubMed PMID: 24694480.
20: Güleç S. Valsartan after myocardial infarction. Anadolu Kardiyol Derg. 2014 Dec;14 Suppl 2:S9-13. doi: 10.5152/akd.2014.00002. Review. PubMed PMID: 25604205.
